Luxna Biotech Co., Ltd. and Takeda Pharmaceutical Company Limited announced that it has entered into an exclusive worldwide license agreement with Takeda Pharmaceutical Company Limited for the use of Luxna’s breakthrough xeno nucleic acid technology for multiple undisclosed target genes in the area of neurological diseases.

Please check here for details.